Viking Therapeutics, Inc. (VKTX) financial statements (2020 and earlier)

Company profile

Business Address 12340 EL CAMINO REAL, SUITE 250
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments276302211314
Cash and cash equivalents825931
Short-term investments267277121013
Other undisclosed current assets81111
Total current assets:284302221415
Noncurrent Assets
Operating lease, right-of-use asset1
Deposits noncurrent assets00 00
Deferred costs    0
Other undisclosed noncurrent assets0001 
Total noncurrent assets:10010
TOTAL ASSETS:284302221515
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities65422
Accounts payable21211
Accrued liabilities44211
Interest and dividends payable  00 
Debt0 33 
Other undisclosed current liabilities  11 
Total current liabilities:75962
Noncurrent Liabilities
Long-term debt and lease obligation0   2
Long-term debt, excluding current maturities    2
Operating lease, liability0
Liabilities, other than long-term debt 0 00
Deferred revenue and credits 00
Deferred rent credit 0
Other undisclosed noncurrent liabilities    3
Total noncurrent liabilities:00 05
Total liabilities:75967
Stockholders' equity
Stockholders' equity attributable to parent2772981389
Common stock00000
Additional paid in capital406401946854
Accumulated other comprehensive income (loss)0(0)(0)(0)(0)
Accumulated deficit(129)(103)(81)(60)(46)
Total stockholders' equity:2772981389
TOTAL LIABILITIES AND EQUITY:284302221515

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Gain (loss) on disposition of assets for financial service operations0(0)
Gross profit:0    
Operating expenses(33)(26)(19)(14)(12)
Other undisclosed operating income (loss)(0)0   
Operating loss:(33)(26)(19)(14)(12)
Nonoperating income (expense)64(2)(1)(11)
Other nonoperating income (expense)74(2)(1)(11)
Loss from continuing operations before income taxes:(26)(22)(21)(15)(23)
Income tax benefit89   
Loss before gain (loss) on sale of properties:(18)(13)(21)(15)(23)
Other undisclosed net loss(7)(9)   
Net loss available to common stockholders, diluted:(26)(22)(21)(15)(23)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(26)(22)(21)(15)(23)
Comprehensive loss:(26)(22)(21)(15)(23)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)(0)0(0)
Comprehensive loss, net of tax, attributable to parent:(25)(22)(21)(15)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: